Tenaya Therapeutics, Inc. Annual Report: Key Insights for the Year Ended December 31, 2025

This summary provides a clear overview of Tenaya Therapeutics, Inc.'s annual report for the fiscal year ending December 31, 2025, highlighting the company's progress and what it means for investors.

Business Overview & Mission Tenaya Therapeutics is a clinical-stage biotechnology company focused on developing innovative treatments for heart disease. The company aims to transform how doctors manage these conditions. As a clinical-stage company, its potential medicines are currently undergoing human trials and are not yet approved for commercial sale. Tenaya advances drug candidates for various heart diseases, including genetic cardiomyopathies and heart failure. These treatments often use cutting-edge approaches like gene therapy and small molecules to address the conditions' root causes.

Financial Performance For the fiscal year ending December 31, 2025, Tenaya Therapeutics reported no significant revenue from product sales. This is typical for a clinical-stage biotechnology company; any revenue primarily comes from collaboration agreements or grants. The company incurred a net loss for the year, reflecting significant investment in research and development. The company clearly relies on external funding.

Risk Factors Investing in Tenaya Therapeutics, a clinical-stage biotechnology company, involves substantial risks. These include:

• Clinical trials: The inherent uncertainty and high failure rate of drug development.
• Regulatory approval: The lengthy and complex approval process by agencies like the FDA.
• Competition: Intense competition from other pharmaceutical and biotechnology companies.
• Capital raising: The company's need to raise additional capital to fund operations and development, which historically leads to significant share dilution through stock offerings and "at-the-market" (ATM) sales.
• Third-party reliance: Dependence on external partners for manufacturing, clinical trials, and research.
• Intellectual property: The ability to protect its patents and other intellectual property.
• Key personnel: Reliance on critical employees.

As a "Smaller reporting company" and an "Emerging growth company," Tenaya has fewer reporting requirements and potentially fewer resources than larger, established firms. This can mean less detailed public information, higher stock price volatility, and potentially less analyst coverage.

Management Discussion and Analysis (MD&A) Highlights The MD&A section offers management's view on the company's financial health and performance. For fiscal year 2025, management highlighted continued investment in research and development (R&D) to advance its pipeline of heart disease treatments. These costs drive most operating expenses. General and administrative (G&A) expenses also contribute to the overall rate of spending.

Notably, the company implemented a workforce reduction on May 14, 2024, likely to manage costs or refocus strategic priorities. A significant development is the ongoing collaboration with Alnylam Pharmaceuticals Inc. This partnership is a key strategic asset. The company's ability to manage operating expenses and secure funding remains critical for its ongoing operations.

Financial Health and Liquidity Tenaya's financial health largely depends on external funding for its research and development. The company actively manages its liquidity through capital raises, such as "Follow-On Offerings" (new stock sales) and "At-The-Market" (ATM) sales agreements throughout 2024 and 2025. While these activities fund operations, they result in dilution for existing shareholders.

As of June 30, 2025, the public float market value of its common stock stood at approximately $63.1 million, with roughly 217 million shares outstanding by March 5, 2026. This indicates a low per-share stock price and significant dilution. The company reports no significant long-term debt, relying instead on equity financing. Maintaining adequate liquidity is paramount for advancing its pipeline and sustaining operations.

Future Outlook and Strategy Tenaya's future depends on successfully moving its drug candidates through preclinical studies and clinical trials, aiming for regulatory approvals from bodies like the FDA. The company's long-term strategy focuses on using its scientific expertise to develop and commercialize innovative heart disease treatments. It continues to invest in its pipeline, targeting specific genetic cardiomyopathies and forms of heart failure.

The ongoing collaboration with Alnylam Pharmaceuticals Inc. also forms a key part of its strategy, potentially offering resources, expertise, and a path to future commercialization. Tenaya aims to continue exploring strategic partnerships and financing opportunities to support its development efforts.

Competitive Position The biotechnology industry, especially in the cardiovascular treatment area, is highly competitive and marked by rapid technological advancements. Tenaya Therapeutics competes with many pharmaceutical, biotech, and medical device companies, often with greater financial, technical, and human resources. Competitors develop similar treatment approaches (e.g., gene therapies, small molecules) or target the same diseases (e.g., genetic cardiomyopathies, heart failure).

Key competitive factors include:

• How well a drug works, its safety, and how well patients tolerate it.
• The timing and cost of development and regulatory approval.
• The ability to obtain and maintain patent protection.
• The ability to attract and retain qualified personnel.